secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001628280-24-000780
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology presents onvansertib data: 73% DCR in 2L KRAS-mut mCRC; FDA Type C meeting supports accelerated path
--------------------------------------------------------------------------------

- 73% disease control rate in 2L KRAS-mutated mCRC; median overall survival 15 months vs ~8 months historical.
- FDA Type C meeting (June 2023) agreed on mCRC development plan supporting potential accelerated approval.
- Topline data from 1st-line RAS-mutated mCRC trial expected mid-2024.
- Cash runway extends into 2025; collaboration with Pfizer under Pfizer Ignite program.
- Preclinical data show onvansertib + bevacizumab reduces tumor size and vascularization in KRAS G12V model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024000780/0001628280-24-000780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024000780/crdf-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-000780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer